Research and Markets has announced the addition of the "World Kidney Fibrosis Treatment Market - Opportunities and Forecasts, 2014 - 2022" report to their offering.

The Kidney fibrosis market is segmented based on therapeutics, location of testing, and geography. Based on the type of treatment, the market is further segmented into Angiotensin Converting Enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARBs), Pirfenidone, Renin Inhibitors and Vasopeptidase Inhibitors.

Based on the location of testing, the market is segmented into hospital, clinic, and home treatments. Currently, hospitals perform a majority of tests and would continue to hold a larger market share, both in terms of volume and revenue of the treatments. Geographically, the global Kidney Fibrosis Treatment Market is segmented into North America, Europe, Asia-Pacific, and LAMEA.

Some of the key players working in the kidney fibrosis treatment market include Merck & Co., F. Hoffman-La Roche Ltd., Pfizer Inc., Galectin Therapeutics, La Jolla Pharmaceutical Company, InterMune Inc., ProMetic Life-Sciences Inc., Genzyme Corporation, BioLine Rx Ltd among others.

KEY MARKET SEGMENTS

KIDNEY FIBROSIS TREATMENT MARKET BY THERAPEUTICS

- Angiotensin II receptor blockers (ARBs)

- Angiotensin Converting Enzyme (ACE) inhibitors

- Pirfenidone

- Renin Inhibitors

- Vasopeptidase Inhibitors

KIDNEY FIBROSIS TREATMENT MARKET BY LOCATION OF THERAPEUTIC

- Hospital testing

Commercial/private hospitals

Public health hospitals

- Clinics

- Home Treatment

KIDNEY FIBROSIS TREATMENT MARKET BY GEOGRAPHY

- North America

- Europe

- Asia-Pacific

- LAMEA

For more information about this report visit http://www.researchandmarkets.com/research/jgfhz2/world_kidney